Apogee Therapeutics, Inc.
APGE
株式のランク
#2363
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its... Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
株価
$135.07
最終同期: 2026-09-04
時価総額
$8.36B
変化（1日）
0.00%
変化（1年）
137.21%
国
US
取引 Apogee Therapeutics, Inc. (APGE)
カテゴリー
Healthcare
Apogee Therapeutics, Inc.（APGE）の利益
Jun 2026 時点の利益 TTM: $-294.09M
Apogee Therapeutics, Inc. の最新の財務報告によると、同社の現在の利益は $-294.09M です。2023 年には $-83.99M の利益を上げ、これは 2022 年の利益 $-39.79M と 減少 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Apogee Therapeutics, Inc. の利益の推移（2022 〜 2026）
各年末の利益
| 年 | 利益 | 変化 |
|---|---|---|
| 2026 (TTM) | $-294.09M | 61.48% |
| 2024 | $-182.13M | 116.86% |
| 2023 | $-83.99M | 111.10% |
| 2022 | $-39.79M | 0.00% |
同業他社の利益
| 企業 | 利益 | 利益の差 | 国 |
|---|---|---|---|
| $5.27B | -1,893.62% |
US
|
|
| $-3.09B | 949.67% |
US
|
|
| $-4.02B | 1,265.62% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -763.28% |
NL
|
